- Can-Fite BioPharma (CANF, Financial) projects $685 million in revenue from partnerships over the next decade.
- The forecast covers key drug candidates targeting psoriasis, advanced liver cancer, pancreatic cancer, and MASH.
- Projected drug launches are expected between 2027 and 2029, subject to regulatory approvals.
Can-Fite BioPharma Ltd. (CANF) has announced an ambitious revenue projection of $685 million over the next ten years, based on the market potential of its lead drug candidates, Piclidenoson and Namodenoson. The revenue forecast is contingent upon regulatory approvals and successful product launches anticipated to occur between 2027 and 2029.
The company's strategy involves leveraging seven partnerships that provide diverse revenue streams. These streams include development and regulatory milestones, commercial sales benchmarks, manufacturing-related transfer payments, and royalties on product sales. The revenue projections span four critical indications: psoriasis, advanced liver cancer, pancreatic cancer, and MASH (Metabolic dysfunction-Associated SteatoHepatitis).
Piclidenoson is currently involved in a pivotal Phase III trial for psoriasis. In parallel, Namodenoson is undergoing a Phase III trial for hepatocellular carcinoma and additional trials for MASH and pancreatic cancer. Both drugs have shown promising results, with Namodenoson granted Orphan Drug and Fast Track Designations by the U.S. FDA for specific uses.
The financial outlook highlights a striking 82x multiple of Can-Fite's current market capitalization of $8.37 million, indicating either market skepticism or potential undervaluation of the company's pipeline. However, the company acknowledges inherent uncertainties in drug development and commercialization, which could impact the realization of these projections.
